| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Famotidine (formerly YM-11170, MK208; MK-208, YM11170; Pepcid) is a competitive histamine H2–receptor antagonist with an IC50 of 0.6 mM. It is frequently used to treat heartburn, GERD, ulcers, and other digestive disorders because it inhibits the production of stomach acid. Famotidine does not appear to interact with other medications, unlike cimetidine, the first H2 antagonist, and it has no effect on the cytochrome P450 enzyme system.
| Targets |
H2 receptor
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C8H15N7O2S3
|
|
|---|---|---|
| Molecular Weight |
337.45
|
|
| Exact Mass |
337.04
|
|
| Elemental Analysis |
C, 28.47; H, 4.48; N, 29.06; O, 9.48; S, 28.51
|
|
| CAS # |
76824-35-6
|
|
| Related CAS # |
Famotidine-13C,d3; 2744683-81-4
|
|
| Appearance |
White to off-white solid powder
|
|
| SMILES |
C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
|
|
| InChi Key |
XUFQPHANEAPEMJ-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
|
|
| Chemical Name |
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9634 mL | 14.8170 mL | 29.6340 mL | |
| 5 mM | 0.5927 mL | 2.9634 mL | 5.9268 mL | |
| 10 mM | 0.2963 mL | 1.4817 mL | 2.9634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04724720 | Active Recruiting |
Drug: Famotidine Drug: Placebo |
Covid-19 | Northwell Health | January 19, 2021 | Phase 2 |
| NCT05077332 | Active Recruiting |
Drug: Famotidine Drug: Celecoxib |
Covid19 COVID-19 Pandemic 2019-nCoV Disease |
Leidos Life Sciences | December 29, 2021 | Phase 2 |
| NCT04724720 | Active Recruiting |
Drug: Famotidine Drug: Placebo |
Covid-19 | Northwell Health | January 19, 2021 | Phase 2 |
| NCT05061303 | Active Recruiting |
Other: Assessment of the drug concentration in the blood |
Kidney Rejection Transplant | Poznan University of Medical Sciences |
October 17, 2021 | N/A |
| NCT04614974 | Active Recruiting |
Drug: Famotidine Other: Speech Language Therapy |
Laryngomalacia Gastro Esophageal Reflux |
Reema Padia | November 18, 2020 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA